News

The Company's SFX-01, a synthetic and stabilised version of sulforaphane, is currently in a Phase II trial, SAS (SFX-01 after Subarachnoid Haemorrhage), in the UK. The orphan drug

Novartis claims that the Expand study is the largest study ever undertaken in SPMS. More than 1,600 people with SPMS from 31 countries participated in the study. They

The priority review status shortens the review clock to six months from the usual 10 months. The agency's action date (PDUFA) is 23 February 2017. Clovis Oncology’s application

The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016

In addition to the storage and transportation of drugs used in clinical trials as a service offered by all of Marken’s depots, Marken’s newest Moscow Depot will now

The unique multitenant cloud capabilities of Veeva Vault enable Daiichi Sankyo to easily streamline management of its critical content, providing external partners, such as CROs, the same level

PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or swelling, across the lining of the

Medivation is focused on the development and commercialization of medically innovative therapies to treat severe diseases that have limited treatment options. The company’s portfolio includes Xtandi (enzalutamide) capsules

The new company, Afimmune, will continue the clinical development of DS102, a novel, anti-fibrotic compound. The company will study DS102 in NASH in addition to certain pulmonary disorders.